What is the difference in craving relief between acamprosate (Campral) and naltrexone for alcohol use disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Difference in Craving Relief Between Acamprosate (Campral) and Naltrexone for AUD

Naltrexone is more effective at reducing alcohol craving and heavy drinking episodes, while acamprosate is more effective at maintaining abstinence once achieved, but naltrexone demonstrates superior craving control particularly when craving intensity is high 1, 2.

Mechanism-Based Differences

Naltrexone's Craving Control

  • Acts as an opioid receptor antagonist that blocks endogenous opioid effects associated with alcohol's rewarding properties 1
  • Controls the craving for alcohol by competitively binding to opioid receptors 3
  • Most effective when craving is highly salient - at higher levels of craving, naltrexone reduces drinking at a significantly greater rate compared to acamprosate 2
  • Works by blocking the euphoric/rewarding effects of alcohol consumption

Acamprosate's Mechanism

  • Functions as an NMDA receptor antagonist with structural similarities to GABA 4
  • Reduces withdrawal symptoms including alcohol craving rather than directly blocking reward pathways 3
  • More pronounced in maintaining rather than inducing remission - must be used in combination with counseling and support 3
  • Not effective in patients who have not been detoxified or become abstinent 3

Clinical Efficacy Differences

Direct Craving Outcomes

Meta-analysis data reveals:

  • Naltrexone has larger effect sizes than acamprosate on reduction of heavy drinking and craving 5
  • Acamprosate has larger effect sizes on maintenance of abstinence but not on craving per se 5
  • Daily diary studies show naltrexone's effect on drinking is mediated through craving reduction, particularly at high craving levels 2

Number Needed to Treat

The 2020 AASLD guidelines specify:

  • Acamprosate: NNT = 12 to prevent return to any drinking 4
  • Naltrexone: NNT = 20 to prevent return to any drinking 4

This suggests acamprosate may be slightly more efficient at preventing any alcohol use, but this reflects abstinence maintenance rather than craving control specifically.

Clinical Application Algorithm

When to Choose Naltrexone for Craving Relief:

  • Patients experiencing high-intensity cravings 2
  • Goal is harm reduction (reducing heavy drinking rather than complete abstinence) 5
  • Patients with low depression levels and low-to-moderate dependence severity 6
  • Can tolerate hepatic metabolism (though hepatotoxicity concerns exist) 4

When to Choose Acamprosate for Craving Relief:

  • After successful detoxification - requires abstinence before starting 5
  • Goal is maintaining abstinence rather than reducing consumption 5
  • Patients with liver disease - no hepatic metabolism, no reported hepatotoxicity 4
  • Craving is primarily withdrawal-related rather than reward-seeking 3

Important Clinical Caveats

Naltrexone Considerations:

  • Requires hepatic metabolism - use caution in liver disease 4
  • Can cause hepatocellular injury 3
  • Requiring abstinence before trial associated with larger effect sizes for both abstinence and reduced heavy drinking 5
  • Not studied specifically in patients with alcoholic hepatitis or cirrhosis 4

Acamprosate Considerations:

  • Renally excreted - adjust for renal dysfunction 4
  • Detoxification before administration associated with better outcomes 5
  • Has NOT been shown to significantly impact alcoholics who have not been detoxified 3
  • No significant benefit over naltrexone or intensive counseling alone in some large trials 3

Comparative Head-to-Head Data:

Recent studies show naltrexone superior to acamprosate in:

  • Time to first relapse (63 vs 42 days) 7
  • Abstinence rates at 1 year (41% vs 17%) 7
  • Abstinence rates at 3 months (63.64% vs 34.68%) 8

However, acamprosate's role in reducing craving was not supported in daily diary studies where craving was directly measured 2.

Bottom Line for Practice

For direct craving relief, naltrexone is the superior choice, particularly when patients experience high-intensity cravings and the goal is reducing heavy drinking 2. Acamprosate's benefit is primarily in maintaining abstinence after detoxification rather than active craving suppression 3, 5. The 2020 AASLD guidelines appropriately list both as FDA-approved options 4, but the mechanistic and clinical data clearly differentiate their roles: naltrexone blocks reward-driven craving, while acamprosate reduces withdrawal-related symptoms that may include craving as a component 1, 3.

References

3
Guideline

alcoholic liver disease.

Hepatology, 2010

7
Research

Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment.

Alcohol and alcoholism (Oxford, Oxfordshire), 2001

Related Questions

Is the current dosing of acamprosate 999 mg twice daily and naltrexone 50 mg daily appropriate, and how should it be adjusted?
In a typical adult with alcohol use disorder who is not taking opioids and has no severe liver disease, which medication is preferred, naltrexone or acamprosate?
In a 48-year-old man who wants to reduce his alcohol consumption but cannot do so on his own, which is the appropriate recommendation: naltrexone, acamprosate, disulfiram, or referral to a 12‑step program?
Is combining acamprosate and naltrexone effective for improving abstinence rates in a patient with alcohol dependence?
What pharmacologic options are available to treat cravings in alcohol use disorder?
In an elderly male with seven explosive bowel movements daily, no abdominal pain, an elevated prostate-specific antigen, and low serum albumin, what is the appropriate diagnostic workup and management?
What are the differential diagnoses for a painful, swollen, warm wrist?
Is it safe to give Lavekan (lavender essential oil product) to a child with attention‑deficit/hyperactivity disorder (ADHD)?
In an adult patient with acute coronary syndrome who has normal renal function (creatinine clearance ≥30 mL/min) and no high‑risk bleeding, is enoxaparin preferred over unfractionated heparin as the anticoagulant?
Can hydrocortisone administration cause resistant hypertension?
When is a definitive diagnosis required for a hepatic hemangioma if contrast‑enhanced MRI is inconclusive, and what subsequent imaging or biopsy investigations should be performed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.